| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Fitzpatrick Alexander A | Chief Legal Officer | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO | /s/ Kathleen Scott, Attorney-in-Fact | 22 May 2025 | 0001398595 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SPRY | Common Stock | Options Exercise | $558,000 | +100,000 | +108% | $5.58 | 192,582 | 20 May 2025 | Direct | F1 |
| transaction | SPRY | Common Stock | Sale | $1,451,513 | -102,969 | -53% | $14.10 | 89,613 | 20 May 2025 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SPRY | Stock Option (Right to Buy) | Options Exercise | $0 | -100,000 | -33% | $0.000000 | 200,000 | 20 May 2025 | Common Stock | 100,000 | $5.58 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Includes 3,355 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024. |
| F2 | The weighted average sale price for the transaction reported was $14.0966 and the range of prices were between $14.02 and $14.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F3 | 25% of the shares subject to the option vested on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. |